{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:59:58Z","timestamp":1787507998356,"version":"build-2736575974"},"reference-count":122,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH\/NCI","doi-asserted-by":"publisher","award":["CA244625"],"award-info":[{"award-number":["CA244625"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cancer cells demand amino acids beyond their usage as \u201cbuilding blocks\u201d for protein synthesis. As a result, targeting amino acid acquisition and utilization has emerged as a pivotal strategy in cancer treatment. In the setting of leukemia therapy, compelling examples of targeting amino acid metabolism exist at both pre-clinical and clinical stages. This review focuses on summarizing novel insights into the metabolism of glutamine, asparagine, arginine, and tryptophan in leukemias, and providing a comprehensive discussion of perturbing their metabolism to improve the therapeutic outcomes. Certain amino acids, such as glutamine, play a vital role in the energy metabolism of cancer cells and the maintenance of redox balance, while others, such as arginine and tryptophan, contribute significantly to the immune microenvironment. Therefore, assessing the efficacy of targeting amino acid metabolism requires comprehensive strategies. Combining traditional chemotherapeutics with novel strategies to perturb amino acid metabolism is another way to improve the outcome in leukemia patients via overcoming chemo-resistance or promoting immunotherapy. In this review, we also discuss several ongoing or complete clinical trials, in which targeting amino acid metabolism is combined with other chemotherapeutics in treating leukemia.<\/jats:p>","DOI":"10.3390\/cancers16061171","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T04:25:15Z","timestamp":1710735915000},"page":"1171","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Enhancing Leukemia Treatment: The Role of Combined Therapies Based on Amino Acid Starvation"],"prefix":"10.3390","volume":"16","author":[{"given":"Can","family":"Chen","sequence":"first","affiliation":[{"name":"Hermans B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46032, USA"},{"name":"Department of Hematology, Affiliated Hangzhou First People\u2019s Hospital, Westlake University School of Medicine, Hangzhou 310006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hermans B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s12276-020-0375-3","article-title":"Amino acids in cancer","volume":"52","author":"Lieu","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmet.2020.06.010","article-title":"Amino Assets: How Amino Acids Support Immunity","volume":"32","author":"Kelly","year":"2020","journal-title":"Cell Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.ircmb.2022.08.001","article-title":"Targeting amino acid metabolism in cancer","volume":"373","author":"Safrhansova","year":"2022","journal-title":"Int. Rev. Cell Mol. Biol"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.2019001034","article-title":"Amino acid metabolism in hematologic malignancies and the era of targeted therapy","volume":"134","author":"Tabe","year":"2019","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41419-024-06435-w","article-title":"Amino acid metabolism in tumor biology and therapy","volume":"15","author":"Chen","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Chiu, M., Taurino, G., Bianchi, M.G., and Bussolati, O. (2021). The role of amino acids in the crosstalk between mesenchymal stromal cells and neoplastic cells in the hematopoietic Niche. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.714755"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.tem.2021.03.003","article-title":"Amino Acid Depletion Therapies: Starving Cancer Cells to Death","volume":"32","author":"Butler","year":"2021","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrc.2016.71","article-title":"From Krebs to clinic: Glutamine metabolism to cancer therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.15252\/embj.201696151","article-title":"Cancer cell metabolism: The essential role of the nonessential amino acid, glutamine","volume":"36","author":"Zhang","year":"2017","journal-title":"EMBO J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.stem.2014.06.002","article-title":"Glucose and glutamine metabolism regulate human hematopoietic stem cell lineage specification","volume":"15","author":"Oburoglu","year":"2014","journal-title":"Cell Stem Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1074\/jbc.RA117.001342","article-title":"The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5)","volume":"293","author":"Cormerais","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature07823","article-title":"c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism","volume":"458","author":"Gao","year":"2009","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"734","DOI":"10.18632\/oncotarget.208","article-title":"Glutaminase: A hot spot for regulation of cancer cell metabolism?","volume":"1","author":"Erickson","year":"2010","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"FDD79","DOI":"10.4155\/fdd-2022-0011","article-title":"Alone and together: Current approaches to targeting glutaminase enzymes as part of anti-cancer therapies","volume":"4","author":"Nguyen","year":"2023","journal-title":"Future Drug. Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2015-01-621870","article-title":"Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition","volume":"126","author":"Jacque","year":"2015","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"18782","DOI":"10.1073\/pnas.0810199105","article-title":"Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction","volume":"105","author":"Wise","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Fan, J., Kamphorst, J.J., Mathew, R., Chung, M.K., White, E., Shlomi, T., and Rabinowitz, J.D. (2013). Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol. Syst. Biol., 9.","DOI":"10.1038\/msb.2013.65"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1172\/JCI69600","article-title":"Glutamine and cancer: Cell biology, physiology, and clinical opportunities","volume":"123","author":"Hensley","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/07357907.2014.907419","article-title":"Importance of glutamine metabolism in leukemia cells by energy production through TCA cycle and by redox homeostasis","volume":"32","author":"Goto","year":"2014","journal-title":"Cancer Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"33542","DOI":"10.1074\/jbc.M113.511170","article-title":"Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells","volume":"288","author":"Pei","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cmet.2020.07.009","article-title":"Induction of a Timed Metabolic Collapse to Overcome Cancer Chemoresistance","volume":"32","author":"Spinelli","year":"2020","journal-title":"Cell Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.2021013201","article-title":"The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation","volume":"139","author":"Amaya","year":"2021","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1158\/1078-0432.CCR-18-3223","article-title":"Targeting Glutamine Metabolism and Redox State for Leukemia Therapy","volume":"25","author":"Gregory","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: Review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"E6669","DOI":"10.1073\/pnas.1603876113","article-title":"ATM\/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia","volume":"113","author":"Gregory","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.exphem.2017.09.007","article-title":"Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia","volume":"58","author":"Gregory","year":"2018","journal-title":"Exp. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood-2017-12-820035","article-title":"Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition","volume":"131","author":"Gallipoli","year":"2018","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-137266","article-title":"AZA + Glutaminase Inhibition with Telaglenastat (CB-839) for Advanced MDS: An Updated Interim Analysis","volume":"136","author":"Saxena","year":"2020","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/blood-2018-99-117433","article-title":"Indoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1 Trial","volume":"132","author":"Emadi","year":"2018","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/leu.2016.219","article-title":"Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: Toxicity data from the UKALL14 trial","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"key":"ref_33","first-page":"2423","article-title":"Asparaginases: Biochemical pharmacology and modes of drug resistance","volume":"32","author":"Avramis","year":"2012","journal-title":"Anticancer. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00280-017-3459-6","article-title":"Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed\/refractory acute myeloid leukemia","volume":"81","author":"Emadi","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/s41375-020-01080-6","article-title":"Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia","volume":"35","author":"Emadi","year":"2021","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1158\/1535-7163.MCT-17-1148","article-title":"We\u2019re Not \u201cDON\u201d Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine","volume":"17","author":"Lemberg","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s42255-019-0039-6","article-title":"Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression","volume":"1","author":"Ni","year":"2019","journal-title":"Nat. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nm.4464","article-title":"Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models","volume":"24","author":"Schulte","year":"2018","journal-title":"Nat. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Jiang, J., Batra, S., and Zhang, J. (2021). Asparagine: A Metabolite to Be Targeted in Cancers. Metabolites, 11.","DOI":"10.3390\/metabo11060402"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"11457","DOI":"10.1038\/ncomms11457","article-title":"Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor","volume":"7","author":"Krall","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1074\/jbc.AC119.011578","article-title":"Glutamine and asparagine activate mTORC1 independently of Rag GTPases","volume":"295","author":"Meng","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3389\/fonc.2019.01480","article-title":"Asparagine Synthetase in Cancer: Beyond Acute Lymphoblastic Leukemia","volume":"9","author":"Chiu","year":"2019","journal-title":"Front Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjh.15924","article-title":"Acute myeloid leukaemia niche regulates response to L-asparaginase","volume":"186","author":"Kaspers","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13045-017-0509-9","article-title":"Drug-induced amino acid deprivation as strategy for cancer therapy","volume":"10","author":"Fung","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2174\/0929867324666171006132729","article-title":"Amino Acid Degrading Enzymes and their Application in Cancer Therapy","volume":"26","author":"Pokrovsky","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100651","DOI":"10.1016\/j.blre.2020.100651","article-title":"Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer","volume":"43","author":"Costa","year":"2020","journal-title":"Blood Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.18632\/oncotarget.2869","article-title":"Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells","volume":"6","author":"Song","year":"2015","journal-title":"Oncotarget"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/BLCTT.S342052","article-title":"Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy","volume":"12","author":"Juluri","year":"2022","journal-title":"Blood Lymphat Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"18674","DOI":"10.1074\/jbc.RA119.010447","article-title":"Promoter demethylation of the asparagine synthetase gene is required for ATF4-dependent adaptation to asparagine depletion","volume":"294","author":"Jiang","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"E7776","DOI":"10.1073\/pnas.1805523115","article-title":"Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response","volume":"115","author":"Nakamura","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1182\/blood-2002-08-2446","article-title":"Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL","volume":"101","author":"Stams","year":"2003","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1158\/1078-0432.CCR-18-1844","article-title":"Epigenetic silencing affects L-asparaginase sensitivity and predicts outcome in T-ALL","volume":"25","author":"Touzart","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1038\/sj.onc.1207498","article-title":"Methylation of the asparagine synthetase promoter in human leukemic cell lines is associated with a specific methyl binding protein","volume":"23","author":"Ren","year":"2004","journal-title":"Oncogene"},{"key":"ref_54","first-page":"985","article-title":"Hypomethylation and reactivation of the asparagine synthetase gene induced by L-asparaginase and ethyl methanesulfonate","volume":"51","author":"Worton","year":"1991","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Serravalle, S., Bertuccio, S.N., Astolfi, A., Melchionda, F., and Pession, A. (2016). Synergistic Cytotoxic Effect of L-Asparaginase Combined with Decitabine as a Demethylating Agent in Pediatric T-ALL, with Specific Epigenetic Signature. Biomed. Res. Int., 2016.","DOI":"10.1155\/2016\/1985750"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.molcel.2014.04.014","article-title":"Mitotic wnt signaling promotes protein stabilization and regulates cell size","volume":"54","author":"Acebron","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ccell.2019.03.004","article-title":"Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias","volume":"35","author":"Hinze","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.molcel.2022.05.025","article-title":"Supramolecular assembly of GSK3alpha as a cellular response to amino acid starvation","volume":"82","author":"Hinze","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41556-019-0347-9","article-title":"ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression","volume":"21","author":"Tameire","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1182\/blood.2021011787","article-title":"BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway","volume":"138","author":"Butler","year":"2021","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1038\/s41388-022-02474-9","article-title":"Asparagine bioavailability regulates the translation of MYC oncogene","volume":"41","author":"Srivastava","year":"2022","journal-title":"Oncogene"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/leu.2014.338","article-title":"L-type amino-acid transporter 1 (LAT1): A therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma\/T-cell acute lymphoblastic leukemia","volume":"29","author":"Rosilio","year":"2015","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0005-2736(01)00384-4","article-title":"Human L-type amino acid transporter 1 (LAT1): Characterization of function and expression in tumor cell lines","volume":"1514","author":"Yanagida","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjh.18218","article-title":"VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse","volume":"198","author":"Heraudet","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00277-023-05495-w","article-title":"Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"103","author":"Fischer","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_66","first-page":"600","article-title":"Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia","volume":"7","author":"Earl","year":"2009","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"E1124","DOI":"10.1152\/ajpendo.00080.2013","article-title":"The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment","volume":"305","author":"Wilson","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"E283","DOI":"10.1152\/ajpendo.00361.2014","article-title":"GCN2 is required to increase fibroblast growth factor 21 and maintain hepatic triglyceride homeostasis during asparaginase treatment","volume":"308","author":"Wilson","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"G1061","DOI":"10.1152\/ajpgi.00052.2016","article-title":"General control nonderepressible 2 deletion predisposes to asparaginase-associated pancreatitis in mice","volume":"310","author":"Mirek","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2579S","DOI":"10.3945\/jn.115.226621","article-title":"Arginine Metabolism Revisited","volume":"146","author":"Morris","year":"2016","journal-title":"J. Nutr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2752S","DOI":"10.1093\/jn\/134.10.2752S","article-title":"Plasma membrane transporters for arginine","volume":"134","author":"Closs","year":"2004","journal-title":"J. Nutr."},{"key":"ref_72","first-page":"512","article-title":"Arginine: Clinical potential of a semi-essential amino acid","volume":"7","author":"Appleton","year":"2002","journal-title":"Altern Med. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.advms.2018.08.018","article-title":"Metabolic pathways of L-arginine and therapeutic consequences in tumors","volume":"64","author":"Szefel","year":"2019","journal-title":"Adv. Med. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nm.4283","article-title":"The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia","volume":"23","author":"Fenouille","year":"2017","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/ijc.31170","article-title":"The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-100","volume":"142","author":"Santo","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2014-09-600643","article-title":"Arginine dependence of acute myeloid leukemia blast proliferation: A novel therapeutic target","volume":"125","author":"Mussai","year":"2015","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1182\/blood-2009-12-258822","article-title":"Pegylated arginase I: A potential therapeutic approach in T-ALL","volume":"115","author":"Hernandez","year":"2010","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1038\/onc.2016.37","article-title":"Arginine dependence of tumor cells: Targeting a chink in cancer\u2019s armor","volume":"35","author":"Patil","year":"2016","journal-title":"Oncogene"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s10637-014-0200-8","article-title":"Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma","volume":"33","author":"Yau","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1073\/pnas.78.5.3235","article-title":"Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA","volume":"78","author":"Major","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1593\/tlo.10265","article-title":"Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts","volume":"4","author":"Glazer","year":"2012","journal-title":"Transl. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.leukres.2013.08.007","article-title":"Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells","volume":"37","author":"Tanios","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_83","unstructured":"Jones, J.B. (1981). The Effect of Arginine Deiminase on Murine Leukemic Lymphoblasts, The University of Oklahoma Health Sciences Center."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1349-7006.1995.tb03094.x","article-title":"Anti-tumor activity of arginine deiminase from Mycoplasma argini and its growth-inhibitory mechanism","volume":"86","author":"Takaku","year":"1995","journal-title":"Jpn J. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/ijc.2910510213","article-title":"In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini","volume":"51","author":"Takaku","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_86","first-page":"240","article-title":"Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers","volume":"8","author":"Shen","year":"2006","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/sj.leu.2401763","article-title":"Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis","volume":"14","author":"Gong","year":"2000","journal-title":"Leukemia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7660","DOI":"10.1200\/JCO.2005.02.0933","article-title":"Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies","volume":"23","author":"Ascierto","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"11253","DOI":"10.1038\/s41598-017-10542-4","article-title":"A phase II study of arginine deiminase (ADI-PEG20) in relapsed\/refractory or poor-risk acute myeloid leukemia patients","volume":"7","author":"Tsai","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2014-10-608133","article-title":"Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo","volume":"125","author":"Ghazaly","year":"2015","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","article-title":"Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment","volume":"122","author":"Mussai","year":"2013","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41586-018-0615-z","article-title":"LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration","volume":"562","author":"Deng","year":"2018","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","article-title":"L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity","volume":"167","author":"Geiger","year":"2016","journal-title":"Cell"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"i L\u00edndez, A.-A.M., Dunand-Sauthier, I., Conti, M., Gobet, F., N\u00fa\u00f1ez, N., Hannich, J.T., Riezman, H., Geiger, R., Piersigilli, A., and Hahn, K. (2019). Mitochondrial arginase-2 is a cell-autonomous regulator of CD8+ T cell function and antitumor efficacy. JCI Insight, 4.","DOI":"10.1172\/jci.insight.132975"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/ijc.32028","article-title":"Targeting the arginine metabolic brake enhances immunotherapy for leukaemia","volume":"145","author":"Mussai","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.1000815","article-title":"IDO induces expression of a novel tryptophan transporter in mouse and human tumor cells","volume":"187","author":"Silk","year":"2011","journal-title":"J. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"9794","DOI":"10.1126\/science.aaf9794","article-title":"Kynurenines: Tryptophan\u2019s metabolites in exercise, inflammation, and mental health","volume":"357","author":"Cervenka","year":"2017","journal-title":"Science"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00726-010-0752-7","article-title":"Tryptophan metabolism, from nutrition to potential therapeutic applications","volume":"41","author":"Otten","year":"2011","journal-title":"Amino Acids"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3324\/haematol.13112","article-title":"High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome","volume":"93","author":"Chamuleau","year":"2008","journal-title":"Haematologica"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ccell.2018.02.005","article-title":"Tumor-Repopulating Cells Induce PD-1 Expression in CD8(+) T Cells by Transferring Kynurenine and AhR Activation","volume":"33","author":"Liu","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood-2006-07-036863","article-title":"Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25 into CD25+ T regulatory cells","volume":"109","author":"Curti","year":"2007","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.it.2009.06.005","article-title":"The aryl hydrocarbon receptor in immunity","volume":"30","author":"Esser","year":"2009","journal-title":"Trends Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.4049\/jimmunol.1900291","article-title":"AhR Activation Leads to Massive Mobilization of Myeloid-Derived Suppressor Cells with Immunosuppressive Activity through Regulation of CXCR2 and MicroRNA miR-150-5p and miR-543-3p That Target Anti-Inflammatory Genes","volume":"203","author":"Neamah","year":"2019","journal-title":"J. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.2217\/fon-2019-0642","article-title":"Role of indoleamine 2,3-dioxygenase in acute myeloid leukemia","volume":"16","author":"Sobash","year":"2020","journal-title":"Future Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tips.2023.04.006","article-title":"Modulation of T cells by tryptophan metabolites in the kynurenine pathway","volume":"44","author":"Stone","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1021\/acs.nanolett.9b02306","article-title":"Redox-activated porphyrin-based liposome remote-loaded with indoleamine 2,3-dioxygenase (IDO) inhibitor for synergistic photoimmunotherapy through induction of immunogenic cell death and blockage of IDO pathway","volume":"19","author":"Liu","year":"2019","journal-title":"Nano Lett."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.exphem.2014.06.006","article-title":"Inhibition of indoleamine 2, 3-dioxygenase by stereoisomers of 1-methyl tryptophan in an experimental graft-versus-tumor model","volume":"42","author":"Lim","year":"2014","journal-title":"Exp. Hematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s12032-010-9459-6","article-title":"Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells","volume":"28","author":"Sallam","year":"2011","journal-title":"Med. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/intimm\/dxh140","article-title":"Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2, 3 dioxygenase","volume":"16","author":"Mellor","year":"2004","journal-title":"Int. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"17073","DOI":"10.1073\/pnas.0806173105","article-title":"Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2, 3 dioxygenase","volume":"105","author":"Muller","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1172\/JCI21583","article-title":"Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes","volume":"114","author":"Munn","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3389\/fonc.2018.00370","article-title":"Indoximod: An immunometabolic adjuvant that empowers T cell activity in cancer","volume":"8","author":"Fox","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1158\/0008-5472.CAN-07-1872","article-title":"Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan","volume":"67","author":"Metz","year":"2007","journal-title":"Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Opitz, C.A., Litzenburger, U.M., Opitz, U., Sahm, F., Ochs, K., Lutz, C., Wick, W., and Platten, M. (2011). The indoleamine-2, 3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019823"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41556-020-00615-4","article-title":"Asparagine enhances LCK signalling to potentiate CD8(+) T-cell activation and anti-tumour responses","volume":"23","author":"Wu","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/s42255-023-00856-1","article-title":"Asparagine restriction enhances CD8(+) T cell metabolic fitness and antitumoral functionality through an NRF2-dependent stress response","volume":"5","author":"Gnanaprakasam","year":"2023","journal-title":"Nat. Metab."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/6\/1171\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:14:48Z","timestamp":1760105688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/6\/1171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":122,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["cancers16061171"],"URL":"https:\/\/doi.org\/10.3390\/cancers16061171","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]}}}